Wnt signaling in ovarian tumorigenesis

International Journal of Gynecological Cancer

Volumn 18, Issue 5, 2008, Pages 954-962

  Gatcliffe, T A ^a   Monk, B J ^a   Planutis, K ^a   Holcombe, R F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ovarian cancer; Tumorigenesis; Wnt signaling

Indexed keywords

BETA CATENIN; CGP 049090; CYTOPLASM PROTEIN; IMATINIB; NUCLEAR PROTEIN; PF 115584; PKF 222815; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

CANCER CLASSIFICATION; CANCER GROWTH; CARCINOGENESIS; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CTNNB1 GENE; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; ENDOMETRIOID CARCINOMA; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CODE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 51749098230     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01127.x     Document Type: Review

References (62)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66.
2. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004 291 : 2705 12.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
4. Jeays-Ward K, Hoyle C, Brennan J et al. Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 2003 130 : 3663 70.
5. Yao HH, Matzuk MM, Jorgez CJ et al. Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn 2004 230 : 210 5.
6. Ricken A, Lochhead P, Kontogiannea M, Farookhi R. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology 2002 143 : 2741 9.
7. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988 319 : 525 32.
8. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998 58 : 1130 4.
9. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998 58 : 1344 7.
10. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999 155 : 527 36.
11. Sagae S, Kobayashi K, Nishioka Y et al. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res 1999 90 : 510 5.
12. Wright K, Wilson P, Morland S et al. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999 82 : 625 9.
13. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS. Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest 2005 60 : 75 83.
14. Satoh S, Daigo Y, Furukawa Y et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000 24 : 245 50.
15. Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer 1997 21 : 233 300.
16. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006 16 : 671 7.
17. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003 1653 : 1 24.
18. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol 2002 4 : 367 73.
19. Parker DS, Jemison J, Cadigan KM. Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. Development 2002 129 : 2565 76.
20. Kramps T, Peter O, Brunner E et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002 109 : 47 60.
21. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 2004 6 : 626 33.
22. Townsley FM, Thompson B, Bienz M. Pygopus residues required for its binding to Legless are critical for transcription and development. J Biol Chem 2004 279 : 5177 83.
23. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001 61 : 8247 55.
24. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001 10 : 116 22.
25. Saegusa M, Okayasu I. Frequent nuclear beta-catena accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001 194 : 59 67.
26. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997 275 : 1787 90.
27. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997 275 : 1790 2.
28. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998 58 : 3526 8.
29. Kildal W, Risberg B, Abeler VM et al. Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 2005 41 : 1127 34.
30. Rask K, Nilsson A, Brannstrom M et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003 89 : 1298 304.
31. Lee CM, Shvartsman H, Deavers MT et al. Beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 2003 88 : 363 8.
32. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS. Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol 2004 23 : 337 46.
33. Zhai Y, Wu R, Schwartz DR et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 2002 160 : 1229 38.
34. Steg A, Wang W, Blanquicett C et al. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 2006 8 : 76 83.
35. Schwartz DR, Wu R, Kardia SL et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003 63 : 2913 22.
36. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006 66 : 1354 62.
37. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005 24 : 73 84.
38. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001 20 : 5878 87.
39. Gray JW, Suzuki S, Kuo WL et al. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 2003 88 : S16 21 discussion S22-4.
40. Caldwell GM, Jones C, Gensberg K et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004 64 : 883 8.
41. Takada T, Yagi Y, Maekita T et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 2004 95 : 741 4.
42. Katoh M. Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol 2005 27 : 1677 83.
43. Rosano L, Spinella F, Di Castro V et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005 65 : 11649 57.
44. Karbova E, Davidson B, Metodiev K, Trope CG, Nesland JM. Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol 2002 10 : 175 80.
45. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett 1999 458 : 247 51.
46. Wang Y, Hewitt SM, Liu S et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer 2006 94 : 686 91.
47. Hoffmans R, Stadeli R, Basler K. Pygopus and legless provide essential transcriptional coactivator functions to armadillo/beta-catenin. Curr Biol 2005 15 : 1207 11.
48. Popadiuk CM, Xiong J, Wells MG et al. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res 2006 12 : 2216 23.
49. Roth LM. Recent advances in the pathology and classification of ovarian sex cord-stromal tumors. Int J Gynecol Pathol 2006 25 : 199 215.
50. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003 21 : 1180 9.
51. Boerboom D, Paquet M, Hsieh M et al. Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res 2005 65 : 9206 15.
52. Boerboom D, White LD, Dalle S, Courty J, Richards JS. Dominant-stable beta-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell tumor model. Cancer Res 2006 66 : 1964 73.
53. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997 39 : 1 20.
54. Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention. Drugs 2002 62 : 945 56.
55. Boon EM, Keller JJ, Wormhoudt TA et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004 90 : 224 9.
56. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 2003 278 : 33067 77.
57. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002 22 : 492 511.
58. Lepourcelet M, Chen YN, France DS et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004 5 : 91 102.
59. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 344 : 1031 7.
60. Zhou L, An N, Haydon RC et al. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 2003 193 : 161 70.
61. Suzuki H, Gabrielson E, Chen W et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002 31 : 141 9.
62. Suzuki H, Watkins DN, Jair KW et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004 36 : 417 22.